Market News

Ionis Reveals Results Study of Vupanorsen

Ionis Pharmaceuticals, Inc. (IONS) announced that Pfizer (PFE) reported positive results from Phase 2b clinical study of vupanorsen.

Based in California, Ionis Pharmaceuticals is a biotechnology company that specializes in discovering and developing human therapeutic drugs.

Vupanorsen, earlier known as IONIS-ANGPTL3-LRx, is an investigational antisense therapy, and is being developed for indications in cardiovascular risk reduction and severe hypertriglyceridemia.

In November 2019, Pfizer licensed vupanorsen from Ionis in a worldwide exclusive agreement. 

See Insiders’ Hot Stocks on TipRanks >>

Results of the Study

Notably, the study met its primary endpoint by achieving statistically significant reduction in non-high-density lipoprotein cholesterol (non-HDL-C) compared to placebo at all doses tested at 24 weeks.

Furthermore, key secondary endpoints were also met and there was a significant reduction in triglycerides and angiopoietin-like-3 at all dose levels reported in subjects treated with vupanorsen.

The company stated that there were no serious adverse events related to the treatment and that the incidents were similar between active and placebo groups.

Management Weighs In

M.D., VP of global cardiovascular development and cardiovascular franchise head at Ionis, Sotirios Tsimikas, commented, “We were pleased to see statistically significant reductions in the primary endpoint, non-HDL-cholesterol, and in the secondary endpoint of triglycerides at all doses tested. The topline results of the Phase 2b study also showed that vupanorsen dose-dependently lowered its target, angiopoietin-like 3.”

He further added, “Pfizer is continuing to review the findings to determine next steps regarding future development. We look forward to the full data set being presented at a medical meeting next year.”

Wall Street’s Take

The Wall Street community is cautiously optimistic about the stock, with a Moderate Buy consensus rating based on 6 Buys, 4 Holds, and 1 Sell. The average Ionis Pharmaceuticals price target of $54 implies 81.45% upside potential to current levels.

Bloggers Weigh In

TipRanks data shows that financial blogger opinions are 100% Bullish on IONS, compared to a sector average of 68%.

Related News:
Guess Posts Q3 Beat and Doubles Dividend; Shares Up 9%
American Eagle Reports Stellar Q3 Beat; Shares Up 4.8%
Nordstrom, Inc. Posts Mixed Q3 Results; Shares Tank 27%

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More